Boehringer Ingelheim GmbH and Zealand Pharma A/S have initiated the Phase III program for their dual agonist of the GLP-1 and glucagon receptors, survodutide, in the treatment of obesity, revealing details on 5 October for three clinical trials designed to demonstrate competitive efficacy and tolerability. After Phase II data showed impressive 18.7% weight loss at the highest dose tested, the Phase III program’s biggest challenge may be to overcome adverse events that led to 28.6% of participants discontinuing treatment.
Key Takeaways
-
Boehringer Ingelheim and Zealand Pharma initiated their Phase III program for GLP-1/glucagon receptor agonist survodutide in obesity with two pivotal trials and a cardiovascular outcomes trial.
-
Survodutide generated significant weight loss in Phase II, but with high discontinuation rates due to adverse events, but a slower titration period in Phase III may reduce gastrointestinal side effect severity
BI and Zealand are developing survodutide (BI 456906) for obesity, but not for type 2 diabetes – unlike GLP-1 agonist class leaders semaglutide, which Novo Nordisk A/S markets as Ozempic for diabetes and Wegovy for obesity, and Eli Lilly and Company’s GLP-1/GIP agonist Mounjaro (tirzepatide), approved in the US for type 2 diabetes and pending Food and Drug Administration approval for obesity later this year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
